Löfgren’s | Non-Löfgren’s | Healthy controls | |
---|---|---|---|
Subjects number | 27 | 30 | 29 |
Age | 39 (28–56)**** | 47 (27–71)**** | 26 (18–42) ¤ |
Sex, female/male | 15/12 | 9/21 | 15/14 |
smoking history (NS/FS/OS/CS) | 20/5/2/0 | 16/13/1/0 | 29/0/0/0 |
Radiograph stages (0,I, II, III, IV, ND) | 0/16/9/0/0/2 | 0/7/9/4/4/6 | 29/0/0/0/0 |
HLA (DR3+/DR3-/ND) | 20/6/1 | 3/24/3 | ND |
BAL analysis | |||
Recovery % | 68 (44–80) | 63,5 (44–84) | 72 (34–88) |
Viability % | 95 (85–99) | 95 (78–98) | 95 (88–98) |
Cell concentration (*106/L) | 225 (49–588)**** | 188 (83,5-476)**** | 90,5 (29–167) ¤ |
Total cell number (*106) | 36 (9–77)**** | 28 (10–81)*** | 16 (5–31,5) ¤ |
BAL differential cell counts | |||
% Macrophages | 68 (39,4-91)**** | 71 (39,70-85)**** | 87 (60,8-97,2) ¤ |
% Lymphocytes | 30 (8,5-57,8)**** | 26 (13–58,2)**** | 11 (2,4-33,7) ¤ |
% Neutrophils | 1,0 (0–5,8) | 1,0 (0–6) | 1,8 (0,2-6) |
% Eosinophils | 0,3 (0–2,5) | 0,3 (0–4,4) | 0,2 (0–1,6) |
CD4/CD8 ratio | 9,6 (1,1-28)**** | 5,8 (1,6 -33)*** | 2,65 (0,9-4,8) ¤ |
Pulmonary function tests | |||
FVC (% of predicted value) | 90 (67–120)**** | 84 (50–105)**** | 111 (86–130) ¤ |
FEV1 (% of predicted value) | 87 (61–104)*** | 82 (46–112)**** | 107 (86–125) ¤ |
TLC (% of predicted value) | 92 (82–123)** | 85 (62–186) # | ND |
DLCO (% of predicted value) | 86 (66–126) | 82 (54–130) | ND |